Gain Therapeutics Q3 2026 Results: Net Loss of $3.16M, Loss Narrows
Gain Therapeutics reported a net loss of $13.4 million for the nine months ended September 30, 2026, with cash and cash equivalents decreasing to $11.7 million from $20.8 million at year-end 2025. The company highlighted its ongoing reliance on additional financing to support its Magellan™ platform and clinical development programs.
- Key figure
- Net loss $3.16M